<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>69</patient-age><report-id>BR-US-EMD Serono, Inc.-7130233</report-id><gender>female</gender><reactions><reaction>NODULE ON RIGHT BREAST (UNDERGONE A SURGERY TO REMOVE THE WHOLE RIGHT BREAST)</reaction><reaction>EMOTIONALLY SUFFERING</reaction><reaction>PAIN ON THE INJECTION SITE</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>REBIF</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Famotidine</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Deflazacort</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Hydrochlorothiazide</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Paroxetin</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Nortriptiline (nortriptyline)</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Cyclobenzaprine</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Acetaminophen</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Metformin</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Zolpidem</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10063399</indication><indication>10070592</indication></indications><outcomes/><country>Brazil</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000510010</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125162937</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">2</safetyreportversion>
    <safetyreportid lang="en">BR-US-EMD Serono, Inc.-7130233</safetyreportid>
    <primarysourcecountry>BR</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>1</reporttype>
    <serious code="1">Yes</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2012-05-02</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-16</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">BR-Merck KGaA-7130233</companynumb>
    <medicallyconfirm>2</medicallyconfirm>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>BR</reportercountry>
      <qualification code="5">Consumer or non-health professional</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientinitial>AAR</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19421228</patientbirthdate>
      <patientsex code="2">Female</patientsex>
      <reaction>
        <primarysourcereaction lang="en">NODULE ON RIGHT BREAST (UNDERGONE A SURGERY TO REMOVE THE WHOLE RIGHT BREAST)</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10006293</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10006272</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="6">unknown</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">EMOTIONALLY SUFFERING</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10014551</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10014551</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome code="6">unknown</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">PAIN ON THE INJECTION SITE</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022086</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022086</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugbatchnumb>AU002057</drugbatchnumb>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>44</drugstructuredosagenumb>
        <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10063399</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>2009-04-24</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>2012-12-05</drugenddate>
        <drugtreatmentduration>4</drugtreatmentduration>
        <drugtreatmentdurationunit code="801">Year</drugtreatmentdurationunit>
        <actiondrug code="1">Drug Withdrawn</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10006272</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10006272</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10014551</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10014551</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022086</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022086</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Famotidine</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Deflazacort</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Hydrochlorothiazide</medicinalproduct>
        <drugstructuredosagenumb>6.25</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Paroxetin</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Nortriptiline (nortriptyline)</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Cyclobenzaprine</medicinalproduct>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Acetaminophen</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Metformin</medicinalproduct>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Zolpidem</medicinalproduct>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical>This solicited case report from a patient in Brazil was initially received at Merck Serono on 02 May 2012. A 69-year old (estimated age at the time of reporting) female patient experienced <Semaphore x="1643615" class="Disease or Finding" value="Breast Lump" score="1.00" ID="C3197">nodule on <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore></Semaphore></Semaphore>(undergone a <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>to remove the whole <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast</Semaphore></Semaphore>), emotionally suffering and <Semaphore x="3040169" class="MedDRA LLT" value="Injection site pain" score="1.00" ID="10022086"><Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>on the <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection site </Semaphore></Semaphore>while being treated with <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.97" ID="249401">Rebif</Semaphore>.The event <Semaphore x="1643615" class="Disease or Finding" value="Breast Lump" score="1.00" ID="C3197">nodule on <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore></Semaphore></Semaphore>(undergone a <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>to remove the whole <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast</Semaphore></Semaphore>) was considered as medically significant by the company.The patient's relevant medical history was not reported.The patient's concomitant medications included <Semaphore x="563497" class="Medicine" value="Famotidine" score="0.49" ID="268139">famotidine </Semaphore><Semaphore x="2420042272604161" class="Medicine - Famotidine - Dose" value="40 mg" score="0.49" ID="">40 mg</Semaphore><Semaphore x="2420119582015489" class="Medicine - Famotidine - Frequency" value="," score="0.49" ID="">, </Semaphore><Semaphore x="435478" class="Medicine" value="deflazacort" score="0.49" ID="249210">deflazacort </Semaphore><Semaphore x="1870239214075905" class="Medicine - deflazacort - Dose" value="5 mg" score="0.49" ID="">5 mg</Semaphore><Semaphore x="1870299343618049" class="Medicine - deflazacort - Frequency" value="," score="0.49" ID="">, </Semaphore><Semaphore x="675434" class="Medicine" value="Hydrochlorothiazide" score="0.49" ID="270905">hydrochlorothiazide </Semaphore><Semaphore x="2900404299890689" class="Medicine - Hydrochlorothiazide - Dose" value="6.25 mg" score="0.49" ID="">6.25 mg</Semaphore><Semaphore x="2900683472764929" class="Medicine - Hydrochlorothiazide - Frequency" value="," score="0.49" ID="">, </Semaphore>paroxetin (<Semaphore x="985375" class="Medicine - Paroxetine - Dose" value="20 mg" score="0.49" ID=""><Semaphore x="985426" class="Medicine" value="Paroxetine" score="0.49" ID="253784">paroxetine</Semaphore>) <Semaphore x="4232153399296001" class="Medicine - Paroxetine - Dose" value="20 mg" score="0.49" ID="">20 mg</Semaphore></Semaphore><Semaphore x="4232260773478401" class="Medicine - Paroxetine - Frequency" value="," score="0.49" ID="">, </Semaphore>nortriptiline (<Semaphore x="934203" class="Medicine - Nortriptyline - Dose" value="10 mg" score="0.49" ID=""><Semaphore x="934242" class="Medicine" value="Nortriptyline" score="0.49" ID="272992">nortriptyline</Semaphore>) <Semaphore x="4012371332825089" class="Medicine - Nortriptyline - Dose" value="10 mg" score="0.49" ID="">10 mg</Semaphore></Semaphore><Semaphore x="4012452937203713" class="Medicine - Nortriptyline - Frequency" value="," score="0.49" ID="">, </Semaphore><Semaphore x="421953" class="Medicine - cyclobenzaprine - Dose" value="150 mg" score="0.49" ID=""><Semaphore x="421996" class="Medicine" value="cyclobenzaprine" score="0.49" ID="248830">cyclobenzaprine </Semaphore>2.5, <Semaphore x="29163" class="Medicine" value="Acetaminophen" score="0.49" ID="239840">acetaminophen </Semaphore><Semaphore x="123136712376321" class="Medicine - Acetaminophen - Dose" value="150 mg" score="0.49" ID="">150 mg</Semaphore></Semaphore>
    <Semaphore x="124193274331137" class="Medicine - Acetaminophen - Frequency" value="," score="0.49" ID="">, </Semaphore><Semaphore x="857859" class="Medicine" value="metFORMIN" score="0.49" ID="279450">metformin </Semaphore><Semaphore x="3684231536443393" class="Medicine - metFORMIN - Dose" value="500 mg" score="0.49" ID="">500 mg </Semaphore><Semaphore x="3684351795527681" class="Medicine - metFORMIN - Frequency" value="and" score="0.49" ID="">and </Semaphore><Semaphore x="1384963" class="Medicine" value="zolpidem" score="0.49" ID="266972">zolpidem </Semaphore>at an unknown dose. No further information was provided.The patient received <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.97" ID="249401">Rebif </Semaphore>(<Semaphore x="735013" class="Medicine" value="Interferon beta-1a" score="0.74" ID="273567"><Semaphore x="735630" class="Medicine" value="Interferon-beta" score="0.49" ID="268564">interferon beta </Semaphore>1a</Semaphore>) at a dose of 44 mcg three times a week from 24 Apr 2009 for <Semaphore x="3115890" class="MedDRA LLT" value="Multiple sclerosis relapse" score="1.00" ID="10048393"><Semaphore x="2451967" class="Disease or Finding" value="Recurrent Disease, Distant Site" score="1.00" ID="C55073">relapsing </Semaphore>remitting <Semaphore x="2245768" class="Disease or Finding" value="Multiple Sclerosis" score="1.00" ID="C3243">multiple sclerosis</Semaphore></Semaphore>. On an unspecified date, the patient presented with <Semaphore x="1643615" class="Disease or Finding" value="Breast Lump" score="1.00" ID="C3197">nodule on <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast</Semaphore></Semaphore></Semaphore>. A <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>was scheduled after cardiologist evaluation. The patient also experienced <Semaphore x="3040169" class="MedDRA LLT" value="Injection site pain" score="1.00" ID="10022086"><Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>on the <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection site </Semaphore></Semaphore>because her <Semaphore x="1864942" class="Disease or Finding" value="Dry Skin" score="1.00" ID="C74592">skin was drier</Semaphore>. On 12 Dec 2012, the patient underwent a <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>in order to remove the whole <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast</Semaphore></Semaphore>. On 05 Dec 2012, <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.97" ID="249401">Rebif </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was discontinued following the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician</Semaphore>'s advice, while the patient had been receiving <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy </Semaphore><Semaphore x="2507513" class="Procedure" value="Sestamibi Scan" score="1.00" ID="C38091">sessions</Semaphore>. The patient was emotionally suffering and did not want to talk about it. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>was aware about the events, but follow up <Semaphore x="1802982" class="Disease or Finding" value="Communication Disorder" score="1.00" ID="C2958">contacts </Semaphore>were not allowed.At the time of reporting, <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events <Semaphore x="1643615" class="Disease or Finding" value="Breast Lump" score="1.00" ID="C3197">nodule on <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore></Semaphore></Semaphore>(undergone a <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>to remove the whole <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast</Semaphore></Semaphore>) and emotionally suffering was not reported and the event <Semaphore x="3040169" class="MedDRA LLT" value="Injection site pain" score="1.00" ID="10022086"><Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>on the <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection site </Semaphore></Semaphore>was not resolved.** Follow up information was received from the patient on 16 Jan 2013. It included the following: event <Semaphore x="1643615" class="Disease or Finding" value="Breast Lump" score="1.00" ID="C3197">nodule on <Semaphore x="2470181" class="AnatomicStructure" value="Right Breast" score="1.00" ID="C47856"><Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore></Semaphore>
       <Semaphore x="2828067" class="MedDRA LLT" value="Breast mass" score="1.00" ID="10006272">
        </Semaphore></Semaphore>
      <Semaphore x="2828067" class="MedDRA LLT" value="Breast mass" score="1.00" ID="10006272">
       </Semaphore>updated to <Semaphore x="1643615" class="Disease or Finding" value="Breast Lump" score="1.00" ID="C3197">nodule </Semaphore>on <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore></Semaphore></Semaphore>(undergone a <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>to remove the whole <Semaphore x="1645054" class="AnatomicStructure" value="Breast" score="1.00" ID="C12971">right <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast</Semaphore></Semaphore>), new non serious event (emotionally suffering) and <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.97" ID="249401">Rebif </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>details (<Semaphore x="1121746" class="Medicine" value="Rebif" score="0.97" ID="249401">Rebif </Semaphore>stop date).** Follow up version was created upon clarification received from the Local Merck affiliate on 24 Jan 2013. It included the following: Patient's <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initials </Semaphore>changed (AAR).</narrativeincludeclinical>
        <sendercomment lang="en">Nodule on right breast (undergone a surgery to remove the whole right breast) [Breast mass] in a 69-year-old (estimated age at the time of reporting) female patient, an unspecified period of time after the first administration of Rebif (interferon beta 1a) for the treatment of relapsing-remitting multiple sclerosis. In addition, the patient experienced the following non serious events: emotionally suffering [Emotional disorder] and pain on the injection site [Injection site pain].
Temporal relationship: potentially compatible. Latency: not assessable (events onset dates not reported).
Dechallenge: not applicable for nodule on right breast  (treatment given), unknown for emotionally suffering (outcome after change not reported) and negative for pain on the injection site.
Alternative explanations: the role of genetic and environmental factors cannot be ruled out. Concomitant treatment with deflazacort, paroxetine, nortriptyline, zolpidem and cyclobenzaprine and concurrent breast nodule could have contributed to the occurrence of emotional disorder.
Evaluation by reporter (patient): not reported.
Evaluation by company: In absence of sufficient information to fully assess the case, nodule on right breast (undergone a surgery to remove the whole right breast) and emotionally suffering have been assessed as causally related to Rebif. Injection site pain is assessed as related to Rebif.
Breast mass and Emotional disorder are unlisted and Injection site pain is listed for Rebif as per reference safety information.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>